(Q30445611)

21 June 2017

1 reference

title

Cyclooxygenase-2 in cervical neoplasia: a review (English)

1 reference

21 June 2017

Jennifer L Young

1

1 reference

21 June 2017

Amir A Jazaeri

series ordinal

2

1 reference

21 June 2017

Christopher J Darus

series ordinal

3

1 reference

21 June 2017

Susan C Modesitt

series ordinal

4

1 reference

21 June 2017

language of work or name

English

0 references

publication date

13 February 2008

1 reference

21 June 2017

1 reference

21 June 2017

109

1 reference

21 June 2017

1

1 reference

21 June 2017

140-145

1 reference

21 June 2017

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Stat bite: worldwide cervical and uterine cancer incidence and mortality, 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Advances in prevention of cervical cancer and other human papillomavirus-related diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

The epidemiology of human papillomavirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Chapter 4: Genital tract infections, cervical inflammation, and antioxidant nutrients--assessing their roles as human papillomavirus cofactors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Mechanisms of disease: Inflammation and the origins of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Smoking is a risk factor for cervical intraepithelial neoplasia grade 3 among oncogenic human papillomavirus DNA-positive women with equivocal or mildly abnormal cytology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

7 January 2021

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Cyclooxygenase-2 transcription is regulated by human papillomavirus 16 E6 and E7 oncoproteins: evidence of a corepressor/coactivator exchange

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-α, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Upregulation of nuclear factor-kappaB (NF-kappaB) is related to the grade of cervical intraepithelial neoplasia, but is not an independent predictor of high-risk human papillomavirus or disease outcome in cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

NSAIDs and cancer prevention: targets downstream of COX-2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Decrease in interferon-gamma production by peripheral blood mononuclear cells in patients with uterine cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Expression of cyclooxygenase-1 and -2 associated with expression of VEGF in primary cervical cancer and at metastatic lymph nodes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

High cyclooxygenase-2 expression is related with distant metastasis in cervical cancer treated with radiotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Synchronous coexpression of epidermal growth factor receptor and cyclooxygenase-2 in carcinomas of the uterine cervix: a potential predictor of poor survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

The combined treatment of aspirin and radiation induces apoptosis by the regulation of bcl-2 and caspase-3 in human cervical cancer cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-kappaB as a possible target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Inhibition of DNA repair as a mechanism of enhanced radioresponse of head and neck carcinoma cells by a selective cyclooxygenase-2 inhibitor, celecoxib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzyme: mechanistic considerations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

The cyclooxygenase-2 selective inhibitor celecoxib suppresses proliferation and invasiveness in the human oral squamous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

A phase II trial of irinotecan, 5-fluorouracil and leucovorin combined with celecoxib and glutamine as first-line therapy for advanced colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

A prospective phase I–II trial of the cyclooxygenase-2 inhibitor celecoxib in patients with carcinoma of the cervix with biomarker assessment of the tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

A Phase II study of acute toxicity for Celebrex (celecoxib) and chemoradiation in patients with locally advanced cervical cancer: primary endpoint analysis of RTOG 0128

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

Cyclooxygenase-2 expression predicts recurrence of cervical dysplasia following loop electrosurgical excision procedure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

The cyclooxygenase-2 inhibitor rofecoxib (Vioxx) in the treatment of cervical dysplasia grade II-III A phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

A randomized double-blind placebo-controlled phase II trial of the cyclooxygenase-2 inhibitor Celecoxib in the treatment of cervical dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.01.008

10.1016/J.YGYNO.2008.01.008

7 January 2021

Identifiers

DOI

1 reference

21 June 2017

1 reference